Skip to main content

Day: May 27, 2021

Clean Power and PowerTap Announces Sponsorship of Andretti Steinbrenner Autosport

VANCOUVER, British Columbia and IRVINE, Calif., May 27, 2021 (GLOBE NEWSWIRE) — Clean Power Capital Corp. (NEO: MOVE)(FWB: 2K6)(OTC: MOTNF) (“Clean Power” or the “Company” or “MOVE”). Clean Power is pleased to announce that PowerTap Hydrogen Fueling Corp. will be featured as the primary sponsor on the No. 17 Indy Lights entry piloted by Devlin DeFrancesco, until December 31, 2023 (the “Term”). Through its wholly-owned subsidiary, PowerTap Hydrogen, Clean Power is focused on the PowerTap intellectual property to develop cost-effective infrastructure for incorporating hydrogen fueling into daily life. The partnership with Andretti Steinbrenner Autosport marks the company’s first venture within the motorsports industry. “We are excited to welcome PowerTap Hydrogen to the Andretti-Steinbrenner partner...

Continue reading

Singular Genomics Systems, Inc. Announces Pricing of Upsized Initial Public Offering of Common Stock

LA JOLLA, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Singular Genomics Systems, Inc. (“Singular Genomics”), a company focused on delivering genomic technologies for the advancement of science and medicine, today announced the pricing of its upsized initial public offering of 10,200,000 shares of its common stock at an initial public offering price of $22.00 per share. All of the shares of common stock are being offered by Singular Genomics. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Singular Genomics, are expected to be $224.4 million. The shares are expected to begin trading on the Nasdaq Global Select Market under the ticker symbol “OMIC” on May 27, 2021. The offering is expected to close on June 1, 2021, subject to the satisfaction of customary...

Continue reading

Thryv Announces Pricing of Upsized Secondary Public Offering of Common Stock by Selling Stockholders

Dallas, May 26, 2021 (GLOBE NEWSWIRE) — Thryv Holdings, Inc. (NASDAQ: THRY) (“Thryv” or the “Company”), today announced the pricing of its previously announced underwritten public offering of 4,238,426 shares of its common stock by certain selling stockholders (the “Selling Stockholders”) at a public offering price of $23.50 per share (the “Offering”). The Offering was upsized from a previously announced offering size of 3,500,000 shares of common stock. The Selling Stockholders have also granted the underwriters a 30-day option to purchase up to an additional 635,763 shares of common stock. The Selling Stockholders will receive all of the proceeds from the Offering. Thryv is not offering any shares of its common stock in the Offering and will not receive any proceeds from the Offering, including from any exercise by the underwriters...

Continue reading

Day One Announces Pricing of Upsized Initial Public Offering

SOUTH SAN FRANCISCO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals, Inc. (Nasdaq: DAWN), a clinical-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for patients of all ages with genetically defined cancers, today announced the pricing of its initial public offering of 10,000,000 shares of its common stock at a public offering price of $16.00 per share. All of the shares are being offered by Day One. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Day One, are expected to be $160.0 million. The shares are expected to begin trading on the Nasdaq Global Select Market on May 27, 2021 under the ticker symbol “DAWN.” The offering is expected to close on June 1, 2021, subject to the satisfaction...

Continue reading

Copper Lake Announces Closing of Second and Final Tranche of Private Placement

TORONTO, May 26, 2021 (GLOBE NEWSWIRE) — Copper Lake Resources Ltd. (TSX-V: CPL, Frankfurt: W0I) (“Copper Lake” or the “Company”) announces that on May 17, 2021, it has closed the second, and final, tranche of the non-brokered private placement (the “Offering”) described in its news release of March 4, 2021. In connection with the final tranche closing of the Offering, the Company issued 100,000 flow-through units (“FT Units”) at a price of $0.065 per FT Unit and 7,455,000 non flow-through units (“NFT Units”) at a price of $0.05 per NFT Unit for gross proceeds of $379,250. Each FT Unit consists of one flow-through common share and one-half of a common share purchase warrant (a “FT Warrant”), with each Warrant being exercisable at $0.10 for 24 months. Each NFT Unit consists of one common share and one Warrant,...

Continue reading

R1 RCM Announces Pricing of Secondary Offering of 15,000,000 Shares by Selling Stockholders

CHICAGO, May 26, 2021 (GLOBE NEWSWIRE) — R1 RCM Inc. (“R1 RCM” or the “Company”) (NASDAQ: RCM) announced that it has priced the underwritten offering of 15,000,000 shares of its common stock by selling stockholders at a price to the public of $22.50 per share. The selling stockholders are TCP-ASC ACHI Series LLLP (“TCP-ASC”), a Delaware series limited liability limited partnership jointly owned by Ascension Health Alliance and investment funds affiliated with TowerBrook Capital Partners L.P., and Joseph Flanagan, the President and Chief Executive Officer of the Company. The underwriters will have a 30-day option to purchase up to an additional 2,250,000 shares of common stock from TCP-ASC. The offering is expected to close on June 1, 2021, subject to the satisfaction or waiver of customary closing conditions. R1 RCM is not selling...

Continue reading

Reyna Silver Announces Brokered Private Placement For Up to C$5.0 Million and Announces Commencement of Drilling at Batopilas

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, British Columbia and HONG KONG, May 26, 2021 (GLOBE NEWSWIRE) — Reyna Silver Corp. (TSXV: RSLV; OTCQB: RSNVF; FRA: 4ZC) (“Reyna” or the “Company“) is pleased to announce that it has entered into an agreement with Eight Capital and Red Cloud Securities Inc. (collectively, the “Agents“) to act as co-lead agents in connection with a best efforts private placement of up to 6,025,000 units of the Company (the “Units“) at a price of C$0.83 per Unit (the “Offering Price“) for gross proceeds of up to C$5,000,750 (the “Offering“). Each Unit will be comprised of one common share of the Company (each, a “Unit Share“) and one half of one common share purchase warrant...

Continue reading

Reviva Announces Pricing of Upsized $30 Million Underwritten Public Offering

CUPERTINO, Calif., May 26, 2021 (GLOBE NEWSWIRE) — Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, announced today the pricing of its upsized underwritten public offering of 8,000,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying investor warrants to purchase up to 6,000,000 shares of common stock. Each share of common stock (or pre-funded warrant in lieu thereof) is being sold together with one investor warrant to purchase 0.75 shares of common stock at a combined effective price of $3.75. The investor warrants will be immediately exercisable...

Continue reading

Ocugen On Track to Submit Emergency Use Authorization Application to U.S. FDA for its COVID-19 Vaccine Candidate, COVAXIN™

Active discussions with FDA related to COVAXIN initiated late last year Master file submitted to FDA on March 26, 2021; awaiting feedback from FDAMALVERN, Pa., May 26, 2021 (GLOBE NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today confirmed its plan to submit its Emergency Use Authorization (EUA) application for COVAXIN to the U.S. Food & Drug Administration (FDA) in June. “Since we have been in discussions with the FDA since late last year, we do not believe that the FDA’s recently revised guidance regarding EUAs raises any concerns about our ability to submit the EUA for COVAXIN as planned, which is currently in process and which we expect to submit...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.